Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Allen Warren Davidoff
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Beta
- 0.08
- Country
- CA
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -6.93
Financials
Net Income
$-1.69MEBITDA
$-1.67MFree Cash Flow
$0.00EPS (diluted)
$-1.05Shares Outstanding (diluted)
1.62M+30137.5%Operating Expenses
$1.67MCash & Debt
$992.9KDividend per Share
$0.07Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-2.66M | $-2.80 |
| 2024 | $0.00 | $-3.15M | $-5.48 |
| 2023 | $0.00 | $-2.16M | $-5.45 |
| 2022 | $0.00 | $-10.45M | $-176.55 |
| 2021 | $0.00 | $-1.66M | $-9.13 |
| 2020 | $0.00 | $-1.28M | $-8.67 |
| 2019 | $0.00 | $-629.6K | $-25.25 |
| 2018 | $0.00 | $-3.78M | $-150.75 |
| 2017 | $0.00 | $-474.2K | $-55.75 |
| 2016 | $0.00 | $-414.8K | $-58.00 |
| 2015 | $0.00 | $-279.3K | $-34.50 |
| 2014 | $0.00 | $-36.9K | $-11.50 |
Valuation
XRTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-50.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·7h ago·Negative
XORTX Re-Engages Investor Relations Program CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TSX Venture Exchange, XORTX has re-engaged IR Agency LLC pursuant to a consulting agreement providing for investor relations and marketing services on substantially the same terms previously disclosed by the Company in its news releases dated May 19, 2026 an
View source ↗ - Newsglobenewswire.com·11d ago·Neutral
…ination and Postponement of Investor Relations Program CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (…
View source ↗
Earnings
Thu, Nov 12(in 2 months)
Typical surprise +29.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Feb 26$-0.45 vs $-0.84beat
- Sat, Nov 15$-0.65 vs $-0.32miss
- Thu, Aug 14$-0.95 vs $-1.25beat
- Mon, May 19$-0.95 vs $-1.35beat
- Thu, May 15$-0.20 vs $-1.45beat
Estimates and results for XRTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.